Open AccessMirabegron in the Management of Overactive Bladder Syndrome
Author(s) -
Miriam O'Kane,
Dudley Robinson,
Linda Cardozo,
Adrian Wagg,
Paul Abrams
Publication year - 2022
Publication title -
international journal of women's health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.136
H-Index - 45
ISSN - 1179-1411
DOI - 10.2147/ijwh.s372597
Subject(s) - mirabegron , overactive bladder , urology , medicine , pathology , alternative medicine
Overactive bladder (OAB) negatively affects work productivity and quality of life in sufferers. Its overall impact is likely to increase as a result of increasing prevalence in an ageing population. The pathophysiology of OAB is not completely understood but the β3-adrenoceptor, which is highly expressed in the urinary bladder, is thought to be important for mediating human detrusor relaxation during the storage phase. Clinical trial results have demonstrated that mirabegron, a selective β3-adrenoceptor agonist offers substantial clinical efficacy and good adherence rates over 12 months. Furthermore, due to its different mechanism of action, it is likely to offer a favourable tolerability profile when compared with antimuscarinic agents, resulting in improved persistence over long-term treatment. Finally, from a health economic perspective, despite its higher drug acquisition cost, mirabegron has been found to be cost-effective, owing to the greater increase in quality-adjusted-life-years gained, when compared to antimuscarinic medications. The PubMed database was searched for English language articles published between 1 January 2005 to 31 January 2022, on the subject of mirabegron. Search terms included "mirabegron", "overactive bladder", "β3-adrenoceptor agonist", "urinary incontinence". This review summarises the evidence for mirabegron as a treatment option for the management of OAB.